Stock SMMT SUMMIT THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
4.65 USD -2.72% Intraday chart for Summit Therapeutics Inc. +5.92% +78.16%
May. 07 Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target MT
May. 01 Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
BU
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
BU
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
BU
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
BU
Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
AQ
Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
BU
Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT
PR
Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT
PR
Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
BU
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023
BU
Summit Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Call on February 20, 2024
AQ
Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024
BU
Summit Therapeutics to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference
AQ
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
AQ
Summit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
BU
Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference
BU
Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BU
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SMMT Stock
  4. News Summit Therapeutics Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW